Iranian journal of Pediatric Hematology and Oncology

en Five-Year Survival, Mortality and Relapse Rate of Childhood Leukemia in Iran: A Systematic Review and Meta-Analysis انکولوژی Oncology مروری سیستماتیک systematic review <div style="border: 1.5pt double windowtext; padding: 1pt 4pt; text-align: justify;">Background: Childhood leukemia (CL) is a cancer that occurs mostly in children and adolescents. A comprehensive image of the survival, mortality, and relapse rate in leukemia in Iran is less visible. Therefore, the current study aimed to estimate the five-year survival, mortality, and relapse rates of CL in Iran. Materials and Methods: The current systematic review and meta-analysis examined all observational studies in English and Persian that were published from January 2000 to July 2024 in different international databases, including Google Scholar, Web of Science, PubMed, Scopus, and local databases such as SID, IranDoc, Magiran, and IranMedex. The statistical heterogeneity was assessed using the I2 index, Tau2, and the Q test. Due to high heterogeneity (I2 > 50%), a random-effect model was used for pooled estimation. The Beggs and Eggers test served to assess the publication bias. Sensitivity analysis was performed to determine the influence of individual studies on the pooled estimate. Results: A total of 22 relevant manuscripts that reported the mortality, survival, and relapse rate of Childhood leukemia were reviewed and analyzed in this study. The 5-year survival rate of childhood leukemia in Iran was 63% (95% CI: 57%- 70%, I2: 94.57, P < 0.001).  The survival rate in ALL and AML cases were 66% (95% CI: 58%- 74%, I2: 95.80, P < 0.001) and 58% (95% CI: 48%- 68%, I2: 83.13, P < 0.001), respectively.  The 5-year mortality and relapse rates in childhood leukemia were also 26% (95% CI: 21%-31%, I2: 89.76, P < 0.001) and 24% (95% CI: 18%-30%, I2: 90.09, P < 0.001), respectively. Conclusion: The 5-year survival rate in Iranian children with leukemia is not very high, and the death and recurrence rates caused by the disease are remarkable. Therefore, developing health and treatment infrastructure to reduce morbidity and improve patient survival is inevitable.</div> Childhood, Leukemia, Mortality, Relapse, Survival 682 700 http://ijpho.ssu.ac.ir/browse.php?a_code=A-10-1185-1&slc_lang=en&sid=1 Mahsa Adibfar Mahsa Adibfar Mazi76@yahoo.com 0009-0009-3149-684X No Department of Pediatrics, Aliasghar Children’s Hospital, School of Medicine, Iran University of Medical Sciences, Tehran, Iran . Department of Pediatrics, Aliasghar Children’s Hospital, School of Medicine, Iran University of Medical Sciences, Tehran, Iran Niloofar Amirniroomand Niloofar Amirniroomand N.amnd.dr@gmail.com 0009-0000-7116-1846 No . Department of Pediatrics, Aliasghar Children’s Hospital, School of Medicine, Iran University of Medical Sciences, Tehran, Iran . Department of Pediatrics, Aliasghar Children’s Hospital, School of Medicine, Iran University of Medical Sciences, Tehran, Iran Shervin Fatehi Shervin Fatehi fatehi68.shervin@gmail.com 0009-0001-9748-3920 No Department of Pediatrics, Aliasghar Children’s Hospital, School of Medicine, Iran University of Medical Sciences, Tehran, Iran . Department of Pediatrics, Aliasghar Children’s Hospital, School of Medicine, Iran University of Medical Sciences, Tehran, Iran Saba Karami Saba Karami saba.karami.68@gmail.com 0009-0009-8058-3632 No Department of Pediatrics, Aliasghar Children’s Hospital, School of Medicine, Iran University of Medical Sciences, Tehran, Iran . Department of Pediatrics, Aliasghar Children’s Hospital, School of Medicine, Iran University of Medical Sciences, Tehran, Iran Mahsasadat Sokout Mahsasadat Sokout Mahsasokout@yahoo.com 0009-0000-1781-4332 Yes Department of Pediatrics, Aliasghar Children’s Hospital, School of Medicine, Iran University of Medical Sciences, Tehran, Iran . Department of Pediatrics, Aliasghar Children’s Hospital, School of Medicine, Iran University of Medical Sciences, Tehran, Iran